Figure 5. CHMFL-074's anti-tumor efficacy in K562 xenograft model.

Female nu/nu mice bearing established K562 tumor xenografts were treated with CHMFL-074 at 25.0, 50.0, 100 mg/kg/d, or vehicle. Imatinib at 100 mg/kg/d served as positive control. Daily oral administration was initiated when K562 tumors had reached a size of 200 to 300 mm³. Each group contained 6 animals. Data, mean ± SEM. (A) Body weight and (B) tumor size measurements from K562 xenograft mice after CHMFL-074 administration. Initial body weight was set as 100%. Non-paired Student's t-test was used to compare the means of two groups and P < 0.05 was considered statistically significant. (C) Representative photographs of tumors in each group after 25.0, 50.0 or 100 mg/kg/d CHMFL-074 or vehicle treatment. Imatinib at 100 mg/kg/d served as positive control (upper panel). Comparison of the final tumor weight in each group after 12-day treatment period. Numbers in columns indicate the mean tumor weight in each group. ns, P > 0.05, *P < 0.05, **P < 0.01 (lower panel). (D) Western blot analysis with antibodies specific to the indicated proteins from tumor lysates prepared from the K562 xenograft mice upon the completion of the indicated treatments. β-Actin is shown as the loading control. (E) Tumor tissue histology of serial section of tumor-bearing mice from each group. Data shows HE, Ki-67 and TUNEL staining. Brown staining indicates positive cells. (Original magnification 200×).